Gene and cell therapies can be life changing but come with expensive price tags. As more therapies are FDA approved, payers are looking for options to control the spiraling cost of specialty pharmacy and to project future financial risk related to new therapies coming to market.
Read moreGene Therapy for Hemophilia A: Valrox may be the world’s most expensive one-time treatment
Should it be approved, BioMarin is considering pricing Valrox, a gene therapy drug aimed at hemophilia A, at $2 million to $3 million for the single treatment.
Read moreZolgensma and Gene Therapy: What is the Cost?
Gene therapy in healthcare has become a reality, and it is set to move from a trickle to a stream in the next few years. This article discusses Zolgensma and other emerging gene therapies in the context of how they may affect a health plan’s costs.
Read moreNew Specialty Pharmacy Program for Summit Re Clients
Summit Reinsurance Services, Inc. today announced a strategic collaboration with RxResults, a pharmacy risk manager. Through this collaboration, Summit Re clients will have access to proprietary informatics, clinical expertise, and business processes to help formulate actionable insights and implement evidence-based strategic initiatives in order to manage pharmacy and specialty pharmacy spend.
Read more